Metastasi cerebrali
EMC - Neurologia, ISSN: 1634-7072, Vol: 12, Issue: 2, Page: 1-22
2012
- 3Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Captures3
- Readers3
Review Description
Si stima che il 25% dei pazienti che soffrono di un cancro svilupperà delle metastasi cerebrali. I cancri del polmone e del seno rappresentano più della metà dei tumori di origine. Il trattamento delle metastasi cerebrali è palliativo. Esso migliora lo stato di quasi tre pazienti su quattro prolungando a volte la durata della vita, ma soprattutto offrendo loro una migliore qualità di vita. La chirurgia e la radiochirurgia stereotassica rappresentano attualmente il trattamento di elezione in pazienti selezionati, ma la radioterapia encefalica in toto rimane il trattamento di riferimento in caso di metastasi multiple che non possono beneficiare dei trattamenti focali. Con l’avvento di terapie mirate e di nuove chemioterapie, il ruolo dei trattamenti sistemici è in corso di rivalutazione.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S1634707212620583; http://dx.doi.org/10.1016/s1634-7072(12)62058-3; https://linkinghub.elsevier.com/retrieve/pii/S1634707212620583; http://linkinghub.elsevier.com/retrieve/pii/S1634707212620583; http://api.elsevier.com/content/article/PII:S1634707212620583?httpAccept=text/xml; http://api.elsevier.com/content/article/PII:S1634707212620583?httpAccept=text/plain; http://dx.doi.org/10.1016/s1634-7072%2812%2962058-3; https://dx.doi.org/10.1016/s1634-7072%2812%2962058-3
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know